top of page
  • Writer's pictureEPA-Insight


ANGLE holds worldwide exclusive option over all megakaryocyte intellectual property

Presence of megakaryocytes in prostate cancer linked to patient survival

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

ANGLE has an option agreement, exercisable up until 14 June 2021, with QMUL for an exclusive worldwide licence over the use of its megakaryocyte intellectual property. The grant of the European patent protects the Company's ability to offer a megakaryocyte-based test in Europe. Similar patents are being pursued in the United States and certain other major territories.

QMUL published research in Clinical Cancer Research in 2017 using ANGLE's Parsortix® system showing that the number of megakaryocyte cells in the blood of prostate cancer patients correlates closely with increased patient survival. This was the first time the presence of these cells in patient blood has been shown to be connected to cancer prognosis and to date no competing system has published success in this area.

Investigation of megakaryocytes in patient blood opens up the potential for a whole new area for cancer prognosis and, at present, ANGLE's patented Parsortix system is the only automated system that has demonstrated the capability of harvesting megakaryocytes. Alternative liquid biopsy approaches such as ctDNA (fragments of dead cells) cannot assess the presence of megakaryocytes.

ANGLE now has the potential for intellectual property protection over the upstream megakaryocyte cell capture technology (its existing Parsortix IP) and the downstream megakaryocyte analysis technology (via its option over the patent grant announced today). The protection of key intellectual property is an essential part of ANGLE's differentiated and highly leveraged product-based commercialisation strategy.

The Parsortix system has previously been shown to be capable of harvesting mesenchymal circulating tumor cells (CTCs), which are linked to a poor patient outcome. Circulating megakaryocytes are linked to a more favourable patient outcome. Combining these two factors may provide new insights into assessing the prognosis of prostate cancer patients, allowing stratified treatment.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We welcome the acceptance of this European patent and are excited by the potential for this entirely new way of assessing cancer through a simple blood test that has been enabled by ANGLE's Parsortix system. We will now be investigating the possibility of adding megakaryocyte tests to our existing CTC tests as part of our sample-to-answer imaging solution under development."

Dr Michele Hill-Perkins, Head of Technology Transfer Biopharma at QMUL Queen Mary Innovation Ltd, commented:

"We are pleased to see the grant of the European patent for the analysis of megakaryocytes in patient blood as a prognostic biomarker with the potential to open up new avenues in the fight against cancer. We look forward to working with ANGLE to bring this analysis to patients as soon as possible."

Dr Yong-Jie Lu, Professor in Molecular Oncology at Barts Cancer Institute, and the Principal Investigator for the megakaryocytes discovery commented:

"We believe megakaryocytes in patient blood may play a key role in the body's immune response to all solid cancer types, not just prostate cancer. We are currently investigating this hypothesis in several other cancer types to maximise the potential of megakaryocyte analysis."


5 views0 comments


bottom of page